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NHS REFORMS
Author? Author?
I guess the coalition must have been aware 
of NHS trusts’ concerns before it published 
the white paper.1 Yet again we go through the 
charade of “consultation.” I try not to get upset 
any more, but one question intrigues me. Who 
were the coalition’s medical advisers in drawing 
up the plans (if there were any)? I can’t find any 
names in the paper itself and nobody has claimed 
“credit” publicly.
My impression is of 
opposition and criticism to 
the plan from the medical 
profession, NHS management, 
and health economists. I have 
read a few supportive letters 
from budding entrepreneurs 
and those wanting to settle old 
scores, but there has been no 
systematic enthusiasm. 
Governments have used 
medical advice from interesting 
sources before, and any 
government might simply 
consult an ambitious cadre of 
party activists within the profession. But I would 
like to see if any of the paper’s medical sources 
of inspiration offer to answer questions from the 
wider profession. If there was no authoritative 
medical advice, at least the profession can’t be 
blamed when things go badly wrong.
David Levine retired physician, Sennen, Cornwall TR19 7AX, UK 
dflreens@hotmail.com
Competing interests: None declared.
1 O’Dowd A. Trusts warn that NHS reforms could 
cause patient care failures and financial chaos BMJ 
2010;341:c5693. (14 October.)
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New ways to harm patients
Where has the idea come from that GPs know the 
cost effectiveness of every intervention during 
their consultations?1
When faced with a clinical problem, I formulate 
a provisional diagnosis and offer patients the 
choice of available treatment options. What 
should I do instead? Omit or misrepresent certain 
treatment options? The better informed patients 
will know the available options, and I am likely to 
be able to fob off only the more deprived patients 
with inferior healthcare.
Whatever the patient chooses, there is no 
gain for me. In the UK capitation based primary 
care there is no supplier induced demand. 
What could I possibly gain from sending 
patients for unnecessary investigations or 
treatment?
The problem for patients is different. 
Because there is no direct cost to them, they 
are likely to opt for even the most marginal 
benefit from investigations or treatment. 
I cannot guide patients to the most cost 
effective option: I can only advise them against 
interventions likely to be harmful.
If I understand it correctly, 
Ruta proposes that GPs 
should have some financial 
gain by denying patients 
care.1 However, this increases 
the chance of patient harm 
and is likely to affect the poor 
more than the rich.
The greatest flaw in the 
proposals is the lack of 
available tools to match 
supply and demand 
sensibly. The white paper 
has already stated that 
care will be comprehensive 
and remain free at the point of use. If care 
cannot be denied, if all services have to be 
commissioned, if GPs cannot introduce user 
charges, then the only remaining option is 
lengthy waiting lists.
Waiting lists are inherently inefficient: more 
consultations for the same problem, more 
administration, and further advanced illness by 
the time the patient gets seen. They also create 
a two tier healthcare system because those 
who can afford it will go private, increasing 
health inequalities.
It is an entertaining thought to ruin the GPs 
who care for the costly poor and ill patients, 
who never asked to be responsible for 
managing a budget, and who just wanted to 
deliver good patient care. I am sure the health 
service will improve no end if we retain only the 
GPs who are most skilled in cream skimming 
the low risk, low cost patients.
Hendrik J Beerstecher GP principal, Sittingbourne, Kent 
ME10 4JA, UK  
hendrick.beerstecher@nhs.net
Competing interests: HJB is a GP principal.
1 Ruta D. GPs should have to take financial responsibility. 
BMJ 2010;341:c5613. (14 October.)
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New ways to harm doctors
Ruta has not thought about the consequences 
of his suggestions.1 Beerstecher has started to 
imagine the consequences,2 but they would be far 
worse.
In Germany all outpatient clinics are managed by 
self employed physicians, GPs, and consultants, 
who are paid according to how many patients 
they treat (with a maximum per patient). Doctors 
who overspend have to explain why and pay 
the excess—a regress—if their reasons are not 
accepted. Until 2001 these reasons were listened 
to and often accepted, but not any more (people 
on regress committees now have to pay if they do 
not “regain” enough). So doctors often have to pay 
back hundreds of thousands of pounds a year, far 
more than they have earned. They can go to court 
and appeal, but this is costly.
When treatments might be costly, GPs send 
patients to a specialist, but because of regress 
the specialist just sends a letter to the GP with the 
recommendation, who then thinks, no, not from 
my budget, and so it goes on. No doctor involved 
in the patient’s care wants his or her budget to be 
used. This has produced more costs and worse 
care.
Doctors caring for ill and poor patients have 
declared bankruptcy and given up their practices 
after decades of hard work. This is one reason why 
rural and poorer regions of Germany have too few 
doctors.
So, when a patient enters your practice you 
really start to pray: “Please, please, don’t let him or 
her be ill.”
Roswitha-E Goetze-Pelka retired psychiatrist, Fearn, Ross-
Shire IV20 1XH, UK  
roswitha.gotze-pelka@virgin.net
Competing interests: R-EG-P worked as a neurology and 
psychiatry specialist in rural Germany for 15 years and has to 
pay more than €700 000 (£608 300; $972 900) in regress 
charges.
1 Ruta D. GPs should have to take financial responsibility. 
BMJ 2010;341:c5613. (14 October.)
2 Beerstecher HJ. New ways to harm patients. BMJ 
2010;341:c6308.
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GLUCOSAMINE AND OSTEOARTHRITIS
Effect size is encouraging
The results and interpretation of the meta-
analysis by Wandel and colleagues of the effects 
of glucosamine and chondroitin on osteoarthritis 
depend on the trials analysed and the thresholds 
defined as clinically relevant.1
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The criteria for the selection of trials is 
questionable; the European Medicines Agency 
recommends evaluating the analgesic effect of 
slow acting drugs for osteoarthritis after at least 
six months of treatment, and the structural effect 
after two years.2 The researchers considered only 
trials with a minimum of 100 patients per arm. 
Instead, a scenario analysis should have been 
performed including smaller studies to assess the 
effects with and without all the clinical data.
Baseline pain values were not taken into 
account; a difference of 0.9 units for severe 
pain (>7) is clinically different from the same 
difference for pain <4. Indeed, in one of the three 
trials of chondroitin on disease modification3 
the baseline pain score was 2.5, thus unlikely to 
decrease by >0.9.
An effect size of >0.39 was arbitrarily defined 
as clinically relevant. However, effect sizes of 
<0.4 are considered to be clinically meaningful. 
Indeed, paracetamol is recommended by the 
European League Against Rheumatism (EULAR) 
and Osteoarthritis Research Society International 
(OARSI), yet its effect size is <0.20.
Wandel and colleagues conclude that the 
effect sizes of chondroitin and glucosamine 
for structure modification are not clinically 
meaningful. These results contradict another 
meta-analysis of chondroitin sulphate with the 
same trials, which showed a difference between 
placebo and chondroitin in joint space width over 
two years of 0.13 mm (P=0.0002), and an effect 
size of 0.23 (P=0.0001).4 In addition, three years 
of glucosamine sulphate treatment reduces the 
incidence of knee replacement by 57% in the next 
five years,5 showing that an effect size of <0.40 is 
clinically meaningful.
Given these limitations, it is inappropriate 
to conclude that pharmaceutically produced 
chondroitin and glucosamine should be 
discouraged for treating osteoarthritis.
Jean-Pierre Pelletier professor of medicine and head, 
Division of Rheumatology, University of Montreal, Canada  
dr@jppelletier.ca
Marc C Hochberg professor of medicine and head, Division 
of Rheumatology and Clinical Immunology, University of 
Maryland School of Medicine, USA 
Patrick du Souich professor and director, Department of 
Pharmacology, Faculty of Medicine, University of Montreal, 
Canada
André Kahan professor of rheumatology and head, Paris 
Descartes University, Faculty of Medicine, and Department of 
Rheumatology A, Cochin Hospital, AP-HP, France
Beat A Michel professor and chair, Department of 
Rheumatology and Institute for Physical Medicine, University 
Hospital Zurich, Switzerland
Competing interests: The authors received research funds 
and lecture fees from various pharmaceutical companies 
involved in the treatment of osteoarthritis with chondroitin 
and/or glucosamine.
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Conclusions not supported by 
methods and results
Wandel and colleagues produced another meta-
analysis of glucosamine in osteoarthritis without 
new evidence when more comprehensive ones 
showed that the quality controlled product 
of glucosamine sulphate for prescription is 
effective.1-4
Their statistical methods are so complex that 
many are mystified by whether the conclusions 
make sense.5 Indeed, we verified that a 
conventional approach gives identical results 
to their network meta-analysis with its poor trial 
selection, as shown by the high heterogeneity.6
They claim low heterogeneity in their 
Bayesian approach, while they used a prior 
distribution with strong emphasis on high 
heterogeneity. Moreover, they derive clinical 
relevance from artificial back transformations 
from the effect size and not from patient or study 
data. Consequently, they surprisingly raise the 
threshold for a clinically relevant effect size from 
0.20 to 0.37. Paracetamol has an effect size 
of 0.14 and non-steroidal anti-inflammatory 
drugs 0.29,2 which is the same as glucosamine 
sulphate in high quality trials2 and the three long 
term trials with the prescription product in which 
heterogeneity disappears.4 These three show an 
effect size of 0.27 or 0.34,4  6 which Wandel and 
colleagues previously considered valuable.1
Network meta-analyses serve mainly to test the 
relative efficacy of drugs by indirect comparison: 
there is no such attempt here. The claim of using 
multiple observations is also misleading since it 
was done in only three out of seven studies; their 
inclusion does not change the results, as we tested.
These and other limitations6 mean that Wandel 
and colleagues’ conclusions are not supported by 
their methods and results.
Giampaolo Giacovelli head, department of biostatistics 
giampaolo.giacovelli@rottapharm.com
Lucio C Rovati chief scientific officer, Rottapharm Madaus, 
20052 Monza, Italy
Competing interests: GG and LCR are scientists from 
Rottapharm, maker of the proprietary formulation of 
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Wandel and colleagues to provide data on their trials that are 
included in the meta-analysis, they immediately agreed to do 
so, but they were never contacted again afterwards.
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Prescribed regimen is effective
In a network meta-analysis of glucosamine 
in osteoarthritis, Wandel and colleagues 
did not separate the three long term trials 
of prescription glucosamine sulphate from 
those using over the counter products lacking 
evidence of efficacy or bioequivalence.1 A 
Cochrane review confirmed that the only 
product showing efficacy is prescription 
glucosamine sulphate 1500 mg once daily.2  3
The authors diluted the efficacy of 
glucosamine sulphate in knee osteoarthritis 
by including two studies of glucosamine 
hydrochloride, a formulation discouraged in 
current guidelines4; they even attributed the 
McAlindon study to glucosamine sulphate 
when it was mostly hydrochloride.5 They also 
included a hip osteoarthritis study of a poor 
quality preparation. Inclusion of the Noack 
study is also questionable since duration was 
only one month. Moreover, use of divided doses 
(500 mg thrice daily) as in the glucosamine 
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hydrochloride studies, impairs bioavailability 
compared with 1500 mg once daily.6
Including all seven studies in a conventional 
meta-analysis results in high heterogeneity 
(I2=63%), making interpretation of the modest 
effect size difficult. Conversely, heterogeneity 
is nil for the three prescription glucosamine 
sulphate long term trials of Reginster et al, 
Pavelka et al, Herrero-Beaumont et al, and the 
effect size is 0.27 for pain and 0.33 for function.3 
Using one of the Bayesian approaches described 
by Wandel and colleagues,1 we found an effect 
size for pain of 0.34 (credible interval 0.08 to 
0.61). These small to moderate effect sizes are 
superior to those of paracetamol and similar to 
those of non-steroidal anti-inflammatory drugs, 
which are universally recommended as first oral 
options for symptomatic osteoarthritis.4
The major limitations of Wandel and 
colleagues’ analysis do not support the strong 
negative conclusions and are harmful to patients: 
rejecting an effective agent is both inappropriate 
and a disservice to the community.
Jean-Yves Reginster president and chair, Department of Public 
Health Sciences, University of Liège, 4000 Liège, Belgium 
jyreginster@ulg.ac.be
Roy D Altman professor of medicine, University of California, 
Los Angeles, 1000 Veterans Avenue, Los Angeles, CA 90024, 
USA 
Marc C Hochberg professor of medicine and epidemiology 
and public health, University of Maryland School of Medicine, 
Baltimore, MD 21201, USA
Competing interest: The authors have received research 
funding and lecturing fees from different pharmaceutical 
companies involved in the treatment of osteoarthritis, 
including glucosamine and chondroitin.
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Authors’ reply
Pelletier and colleagues question the exclusion 
of small studies,1 although we have recently 
shown that small studies often distort results 
of meta-analyses of osteoarthritis trials, 
particularly for glucosamine and chondroitin 
trials.2 The issues of different types of 
glucosamine and differences in the quality and 
bioequivalence of preparations were examined 
in figure 3 of our report, without evidence to 
suggest that either will explain our results.
Giacovelli and Rovati suggest several errors 
in our classification of trials,3 which we were 
unable to confirm after careful re-examination 
of our data. The apparent misclassification of 
the trial by McAlindon regarding the type of 
glucosamine used is related to ambiguities in 
published information.4  5 The primary report 
states, “the switch from the Physiologics 
to Rotta glucosamine product occurred at 
enrolment of the 163rd participant.”4 The 
description of the preparations confirms that the 
Physiologics preparation contained glucosamine 
sulphate. Since no correction of the original trial 
report is available to date we continue to adhere 
to our classification.
Contrary to the three letters,1  3  5 we have 
explored thoroughly the variation of effect 
of preparations over time. Figure 2 of our 
report and published results of accompanying 
statistical tests suggest that variation over time 
is no greater than that expected by chance alone 
(P=0.93 for interaction between treatment 
effect and time). With a tau-squared estimate of 
0.04, between trial heterogeneity was indeed 
low. We are unable to reproduce the estimate of 
Reginster and colleagues5 but emphasise that 
the large size of included studies means that I2 
estimates may be unduly inflated, although the 
variation between trials is small.6
The cut-off points used to delineate the 
minimal clinically important difference were not 
based on Cohen’s seminal work from the 1970s,7 
as suggested by Pelletier et al,1 but on the median 
minimal clinically important difference found in 
recent studies in patients with osteoarthritis, as 
referenced in the methods section of our report. 
We agree that treatment effects of paracetamol 
are concerningly small, but effect sizes found in 
large trials of non-steroidal anti-inflammatory 
drugs (NSAIDs) and paracetamol using identical 
outcome definitions as those referred to in our 
report are larger than suggested by Giacovelli and 
Rovati3—0.38 for oral NSAIDs (95% confidence 
interval 0.49 to −0.27) and −0.25 for paracetamol 
(0.39 to −0.11).2
Observed treatment effects for both 
glucosamine and chondroitin compared with 
placebo are irrelevant to undetectable. With the 
observed differences in pain intensity of 0.3 to 
0.5 cm between food supplements and placebo 
on a 10 cm visual analogue scale, the distribution 
of pain scores in patients receiving supplements 
and placebo are nearly identical.7  8 Therefore, we 
maintain that it would be impossible, on the basis 
of the reported pain intensity at the end of a trial, 
to determine whether a patient was allocated to a 
food supplement or placebo.
Peter Jüni professor and head of division
juni@ispm.unibe.ch 
Eveline Nüesch research fellow, 
Sven Trelle senior research fellow, Institute of Social and 
Preventive Medicine, University of Bern, and CTU Bern, Bern 
University Hospital, Switzerland
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DATA OPENNESS
Don’t forget preclinical science
During the 1990s the pharmaceutical industry 
developed various atypical antipsychotic drugs 
that were contrasted favourably with older 
typical antipsychotics. Recent independent trials 
and meta-analyses indicate that the effects of 
the atypicals were exaggerated and that the 
existence of the drugs as a class is spurious, 
partly because of selective publication of clinical 
trial data.1-3
After these publications I recalled an 
indiscreet comment made many years ago 
by a senior preclinical scientist involved in 
developing an atypical, to the effect that 
atypicals did not differ from a low dose of 
haloperidol—the prototype older antipsychotic. 
I emailed him for his thoughts on the surprising 
recent clinical evidence. He indicated 
that he found the evidence unsurprising 
as his company had conducted extensive 
unpublished preclinical studies comparing 
an appropriate low dose of haloperidol with 
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clozapine, the prototypical atypical, and 
observed no differences. Thus it is not only 
clinical trial data that are missing4: preclinical 
data of substantial importance are also 
missing.
Ultimately, preclinical studies related to drug 
development and basic science are validated in 
terms of accepted clinical findings. Many studies 
in animals have been conducted with atypicals. 
Many of these will have been conducted 
because of the now contentious clinical 
findings. Missing clinical and preclinical data 
do not simply mislead clinicians: they mislead 
preclinical scientists also.
Andrew J Goudie reader in psychopharmacology, School 
of Psychology, Eleanor Rathbone Building, Liverpool 
University, L69 3BX, UK  
ajg@liverpool.ac.uk
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Maintaining trust
Trust in clinical research and its medical reporting 
lies at the heart of improving patient care whether 
the clinical research is sponsored by industry or 
academia.
Steinbrook and Kaiser assert that industry 
cannot be relied on to provide dispassionate 
evaluations of its own drugs and medical devices.1 
They forget the rigorous internal and external 
control framework governing the conduct and 
reporting of clinical trials, including review by 
regulatory authorities and ethics committees.
They suggest greater access to trial databases. 
Investigators for GlaxoSmithKline studies can 
already review the entire database relating to 
the trial. We at GlaxoSmithKline are also open to 
further discussion of providing confidentially to 
medical journals the data on which manuscripts 
are based as part of the peer review process. 
Those with access to such data would have to 
be accountable for using them responsibly and 
for protecting patient confidentiality. Practical 
issues relating to the size and complexity of the 
databases would also need to be addressed.
We are committed to ensuring that the results 
of all the clinical studies evaluating our drugs are 
in the public domain.2 We welcome constructive 
discussions on ways trust can be strengthened 
further in the conduct and reporting of clinical 
research.
Pim Kon medical director medinfo@gsk.com
Andrew Freeman director, medical advocacy and policy, 
GlaxoSmithKline UK, Stockley Park, Uxbridge, Middlesex 
UB11 1BT, UK
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CHILEAN MINERS
Let’s hope doctor is  
misquoted
I hope that the doctor looking after the 
psychological health of the miners was 
misquoted or mistranslated, but if he did 
say, “Now the men are starting to demand 
certain things, and we restrict others. We are 
measuring each other’s strength” and that the 
miners would be rewarded if they cooperated 
but “If not, okay, you don’t want to speak to 
psychologists? Perfect. That day you get no 
television; there is no music—because we 
administer these things” then something is 
amiss.1
As McCartney points out,1 the evidence 
from the literature is now clear. Single session 
psychological debriefing not only does not work, 
it probably increases the risk of subsequent 
psychological disorder. In 1999 when 
colleagues and I wrote the first Cochrane review 
on this, cited by McCartney, we concluded on 
the basis of available evidence that “compulsory 
debriefing must cease.” This evidence has 
strengthened, not diminished, over time.
These men are not mentally ill. They have 
shown considerable resilience in the face 
of adversity, sustained by their own social 
networks and support. This must be respected 
and every effort made to ensure that this 
solidarity continues. A small number may 
develop mental health problems, including 
post-traumatic stress disorder. At such a time, 
evidence based psychological therapies should 
be made available, but only on the basis of 
consent, never coercion.2
There is no justification for treating the 33 
miners as mentally ill, or even likely to become 
so, not least because this could become a self 
fulfilling prophecy. Instead, better to assume 
that they are the robust, resilient people that 
they have been to date, maintain a discrete 
supportive contact, and be available if and 
when a few do need psychological help.
Simon Wessely professor of psychological medicine, 
Institute of Psychiatry, King’s College  
London, London, UK simon.wessely@kcl.ac.uk
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JOURNALS AND CONSENT FORMS
Policy needs to be revisited
Consent should be obtained before publishing 
case reports.1 Signed consent forms include 
patient’s name and the manuscript title, which 
often states the illness. Several UK journals insist 
that consent forms are sent to their editorial 
offices.
In the UK, processing of personal data is 
governed by the Data Protection Act 1998.2  3 
Disclosure of sensitive personal data needs the 
explicit consent of the patient.2 But such consent 
is different from the disclosure of patients’ 
names to journals, and this matter needs further 
clarification. Case reports have a high rejection 
rate so large amounts of named health data are 
accessible at publishing houses for no good 
reason.
We don’t understand how a signed consent 
form is of value as regards its authenticity. We 
believe journals should place more trust in 
authors’ attestation of consent. Forms could 
be archived in the patient’s records or possibly 
with the Caldicott Guardian. If not, forms 
should make it explicit to patients that they are 
giving permission for the clinical material to be 
published and for the transfer of their personal 
verification. Patients should be advised that 
their sensitive and named personal data will be 
stored by the publisher indefinitely and would be 
accessible to staff.
Authors are responsible for data transfer but 
journals should revisit their requirements that 
facilitate the process.
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